FDA Issues Letter to Industry on DSHEA Disclaimer - WholeFoods Magazine
FDA issued a letter to the dietary supplement industry emphasizing the proper use of the DSHEA disclaimer for products bearing structure/function claims. The letter clarifies that the disclaimer must be prominently displayed and not buried in fine print, and warns against misleading claims that imply drug-like effects.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Supplement brands, contract manufacturers, private-label sellers, and ingredient suppliers making structure/function claims on labels or marketing materials. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; FDA may issue warning letters at any time. Prioritize high-risk products (e.g., those with bold claims or small disclaimers).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA reinforced enforcement of the DSHEA disclaimer requirement, signaling increased scrutiny and potential for warning letters or enforcement actions if disclaimers are not properly displayed or if claims cross into drug territory.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, and ingredient suppliers making structure/function claims on labels or marketing materials.
What you must do
Review all product labels and marketing materials to ensure the DSHEA disclaimer ("This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.") is prominently placed, in clear readable font, and not obscured. Also verify that structure/function claims are substantiated and do not imply disease treatment.
Deadline
Immediately; FDA may issue warning letters at any time. Prioritize high-risk products (e.g., those with bold claims or small disclaimers).
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- After 4-year review, FDA shuts down attempt to regulate CBD as a supplement and asks Congress for help - AgencyIQ by POLITICO
- Texas Updates Food Labeling Law: 44 Ingredients Require Warning Labels - CIRS Group
- Draft Guidance on NDIN Master Files for Dietary Supplements - fda.gov
- Listing of Color Additives Exempt From Certification; Spirulina Extract
- Listing of Color Additives Exempt From Certification; Butterfly Pea Flower Extract; Confirmation of Effective Date